MT3 and metastatic malignant neoplasm in the lymph nodes: Gomulkiewicz et al. (31) demonstrated that patients with ductal breast cancer had lower expression of MT3 than that in non-malignant breast tissue and the level of MT3 in breast cancer patients with lymph node metastasis decreased compared to patients without metastasis.